Coenzyme Q10 and spinocerebellar ataxias. Lo, R. Y., Figueroa, K. P., Pulst, S. M., Lin, C., Perlman, S., Wilmot, G., Gomez, C., Schmahmann, J., Paulson, H., Shakkottai, V. G., Ying, S., Zesiewicz, T., Bushara, K., Geschwind, M., Xia, G., Subramony, S. H., Ashizawa, T., & Kuo, S. Movement Disorders: Official Journal of the Movement Disorder Society, 30(2):214–220, 02, 2015. doi abstract bibtex The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.
@article{lo_coenzyme_2015,
title = {Coenzyme {Q10} and spinocerebellar ataxias},
volume = {30},
issn = {1531-8257},
doi = {10.1002/mds.26088},
abstract = {The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.},
language = {eng},
number = {2},
journal = {Movement Disorders: Official Journal of the Movement Disorder Society},
author = {Lo, Raymond Y. and Figueroa, Karla P. and Pulst, Stefan M. and Lin, Chi-Ying and Perlman, Susan and Wilmot, George and Gomez, Christopher and Schmahmann, Jeremy and Paulson, Henry and Shakkottai, Vikram G. and Ying, Sarah and Zesiewicz, Theresa and Bushara, Khalaf and Geschwind, Michael and Xia, Guangbin and Subramony, S. H. and Ashizawa, Tetsuo and Kuo, Sheng-Han},
month = 02,
year = {2015},
pmid = {25449974},
pmcid = {PMC4674072},
keywords = {Humans, Age of Onset, Aged, Female, Male, Adult, Middle Aged, Spinocerebellar Ataxias, Surveys and Questionnaires, Disease Progression, Treatment Outcome, Severity of Illness Index, coenzyme Q10, Huntington Disease, neurodegeneration, spinocerebellar ataxias, statins, Ubiquinone},
pages = {214--220}
}
Downloads: 0
{"_id":"Gk3mo9ecExB9rYeW7","bibbaseid":"lo-figueroa-pulst-lin-perlman-wilmot-gomez-schmahmann-etal-coenzymeq10andspinocerebellarataxias-2015","author_short":["Lo, R. Y.","Figueroa, K. P.","Pulst, S. M.","Lin, C.","Perlman, S.","Wilmot, G.","Gomez, C.","Schmahmann, J.","Paulson, H.","Shakkottai, V. G.","Ying, S.","Zesiewicz, T.","Bushara, K.","Geschwind, M.","Xia, G.","Subramony, S. H.","Ashizawa, T.","Kuo, S."],"bibdata":{"bibtype":"article","type":"article","title":"Coenzyme Q10 and spinocerebellar ataxias","volume":"30","issn":"1531-8257","doi":"10.1002/mds.26088","abstract":"The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.","language":"eng","number":"2","journal":"Movement Disorders: Official Journal of the Movement Disorder Society","author":[{"propositions":[],"lastnames":["Lo"],"firstnames":["Raymond","Y."],"suffixes":[]},{"propositions":[],"lastnames":["Figueroa"],"firstnames":["Karla","P."],"suffixes":[]},{"propositions":[],"lastnames":["Pulst"],"firstnames":["Stefan","M."],"suffixes":[]},{"propositions":[],"lastnames":["Lin"],"firstnames":["Chi-Ying"],"suffixes":[]},{"propositions":[],"lastnames":["Perlman"],"firstnames":["Susan"],"suffixes":[]},{"propositions":[],"lastnames":["Wilmot"],"firstnames":["George"],"suffixes":[]},{"propositions":[],"lastnames":["Gomez"],"firstnames":["Christopher"],"suffixes":[]},{"propositions":[],"lastnames":["Schmahmann"],"firstnames":["Jeremy"],"suffixes":[]},{"propositions":[],"lastnames":["Paulson"],"firstnames":["Henry"],"suffixes":[]},{"propositions":[],"lastnames":["Shakkottai"],"firstnames":["Vikram","G."],"suffixes":[]},{"propositions":[],"lastnames":["Ying"],"firstnames":["Sarah"],"suffixes":[]},{"propositions":[],"lastnames":["Zesiewicz"],"firstnames":["Theresa"],"suffixes":[]},{"propositions":[],"lastnames":["Bushara"],"firstnames":["Khalaf"],"suffixes":[]},{"propositions":[],"lastnames":["Geschwind"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Xia"],"firstnames":["Guangbin"],"suffixes":[]},{"propositions":[],"lastnames":["Subramony"],"firstnames":["S.","H."],"suffixes":[]},{"propositions":[],"lastnames":["Ashizawa"],"firstnames":["Tetsuo"],"suffixes":[]},{"propositions":[],"lastnames":["Kuo"],"firstnames":["Sheng-Han"],"suffixes":[]}],"month":"02","year":"2015","pmid":"25449974","pmcid":"PMC4674072","keywords":"Humans, Age of Onset, Aged, Female, Male, Adult, Middle Aged, Spinocerebellar Ataxias, Surveys and Questionnaires, Disease Progression, Treatment Outcome, Severity of Illness Index, coenzyme Q10, Huntington Disease, neurodegeneration, spinocerebellar ataxias, statins, Ubiquinone","pages":"214–220","bibtex":"@article{lo_coenzyme_2015,\n\ttitle = {Coenzyme {Q10} and spinocerebellar ataxias},\n\tvolume = {30},\n\tissn = {1531-8257},\n\tdoi = {10.1002/mds.26088},\n\tabstract = {The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Movement Disorders: Official Journal of the Movement Disorder Society},\n\tauthor = {Lo, Raymond Y. and Figueroa, Karla P. and Pulst, Stefan M. and Lin, Chi-Ying and Perlman, Susan and Wilmot, George and Gomez, Christopher and Schmahmann, Jeremy and Paulson, Henry and Shakkottai, Vikram G. and Ying, Sarah and Zesiewicz, Theresa and Bushara, Khalaf and Geschwind, Michael and Xia, Guangbin and Subramony, S. H. and Ashizawa, Tetsuo and Kuo, Sheng-Han},\n\tmonth = 02,\n\tyear = {2015},\n\tpmid = {25449974},\n\tpmcid = {PMC4674072},\n\tkeywords = {Humans, Age of Onset, Aged, Female, Male, Adult, Middle Aged, Spinocerebellar Ataxias, Surveys and Questionnaires, Disease Progression, Treatment Outcome, Severity of Illness Index, coenzyme Q10, Huntington Disease, neurodegeneration, spinocerebellar ataxias, statins, Ubiquinone},\n\tpages = {214--220}\n}\n\n","author_short":["Lo, R. Y.","Figueroa, K. P.","Pulst, S. M.","Lin, C.","Perlman, S.","Wilmot, G.","Gomez, C.","Schmahmann, J.","Paulson, H.","Shakkottai, V. G.","Ying, S.","Zesiewicz, T.","Bushara, K.","Geschwind, M.","Xia, G.","Subramony, S. H.","Ashizawa, T.","Kuo, S."],"key":"lo_coenzyme_2015","id":"lo_coenzyme_2015","bibbaseid":"lo-figueroa-pulst-lin-perlman-wilmot-gomez-schmahmann-etal-coenzymeq10andspinocerebellarataxias-2015","role":"author","urls":{},"keyword":["Humans","Age of Onset","Aged","Female","Male","Adult","Middle Aged","Spinocerebellar Ataxias","Surveys and Questionnaires","Disease Progression","Treatment Outcome","Severity of Illness Index","coenzyme Q10","Huntington Disease","neurodegeneration","spinocerebellar ataxias","statins","Ubiquinone"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/network/files/3bMoSK6CwZ5CStTkE","dataSources":["mpF5BsQ6ZZXRpsesy","LoZvzyxt6SHJagniw","Wmoq6R6JBZFa7bo7g","bpAGCJAQgu3TEsYWr","qZXKwWwMbevNtraxF","yazmnFwJHxYEXzK4Z","Dtf2y3TcmfsfwseKf","pRQ79W6n6gWfP9HTj","YDfHouAQGJJNoDwhd","nMhdKXzBdyBhiaDL6"],"keywords":["humans","age of onset","aged","female","male","adult","middle aged","spinocerebellar ataxias","surveys and questionnaires","disease progression","treatment outcome","severity of illness index","coenzyme q10","huntington disease","neurodegeneration","spinocerebellar ataxias","statins","ubiquinone"],"search_terms":["coenzyme","q10","spinocerebellar","ataxias","lo","figueroa","pulst","lin","perlman","wilmot","gomez","schmahmann","paulson","shakkottai","ying","zesiewicz","bushara","geschwind","xia","subramony","ashizawa","kuo"],"title":"Coenzyme Q10 and spinocerebellar ataxias","year":2015}